NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: When was the last time you recovered money for shareholders?

Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...

While Nevro recorded income of around $408 million, Globus Medical's sales at $2.52 billion showed a 60.6% annual rise year ...

Globus Medical (GMED), a musculoskeletal solutions company, Thursday agreed to acquire Nevro Corp. (NVRO), a medical device company, ...

Stifel Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) an “unexpected move.” The firm says that while it wants to be ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. to Globus Medical for $5.85 per share is fair to Nevro shareholders. Halper Sadeh encourages Nevro ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

AUDUBON, Pa. - Globus Medical , Inc. (NYSE: NYSE:GMED), a prominent musculoskeletal solutions company with a market capitalization of $11.81 billion and an "GREAT" financial health rating according to ...

Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Despite political, market, and economic uncertainties, we expect a low single-digit percent growth for 2025 full-year revenue and an EBIT margin of around 16 percent. Let me thank my colleagues for ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.